OXIS International, Inc. (OTCMKTS:OXIS) confirmed that trading in OXIS common stock resumed on reputed Euronext Paris in the second week of April. However, the trading mode has been changed this time. Now they trade in a new form that is popularly called as “double call auction trading mode”. The new trading mode falls in the category of fixed trading mode and is entirely different from the initial continuous trading mode.
Talking about the recent change in the trading mode, the company’s CEO stated that the new mode will support efficient trading. The company can witness improved volume on both the Euronext Paris and OTC Bulletin marketplace. The change in trading mode received approval from Euronext Paris.
In unrelated news, the CEO of OXIS attended Business of Biotech conference that was held on April 17, 2015. The conference was organized at the Moffitt Cancer Center and highlighted the theme of “Collaborate to Innovate.” It was the ninth conference of Business of Biotech wherein the industry leaders talked about the latest trends and advancements associated with generation of capital.
OXIS management highlighted the different fundraising opportunities and important changes seen in the evolving life science firms. The conference was a mega event and was attended by executives from renowned companies such as Signal Genetics Inc (NASDAQ:SGNL) and Cvergenx, Lion Biotechnologies Inc (NASDAQ:LBIO).
The management of OXIS is optimistic on the company’s growth plans in the future. The company is well-placed to take a step forward and expand its operations with advanced technologies. It operates in the growing market of immunotherapeutics in the cancer therapies industry.
In last trading session, the share price of OXIS declined more than 1.00% to close the trading session at $0.0300. The drop came at a share volume of 5.27 million compared to average volume of 5.09 million.